Pelthos CEO to Discuss Strategy at ROTH Conference
Event summary
- Pelthos Therapeutics CEO Scott Plesha to participate in fireside chat at 38th Annual ROTH Conference on March 23, 2026, at 3:00 p.m. PT.
- Live webcast available on Pelthos website; replay accessible for 90 days post-event.
- Pelthos focuses on cutaneous infectious disease treatments, with ZELSUVMI™ as lead product for Molluscum contagiosum.
- Portfolio includes Xepi® for impetigo and Xeglyze® for head lice.
The big picture
Pelthos Therapeutics is positioning itself as a key player in the dermatological space, focusing on unmet needs in cutaneous infectious diseases. The company's participation in the ROTH Conference underscores its strategy to engage with investors and highlight its differentiated product portfolio. The biopharmaceutical sector continues to see consolidation and innovation, with Pelthos aiming to carve out a niche in specialized dermatological treatments.
What we're watching
- Product Differentiation
- How Pelthos can sustain competitive edge with ZELSUVMI™ as the only at-home treatment for Molluscum contagiosum.
- Market Expansion
- The pace at which Pelthos can expand its portfolio into additional dermatological indications.
- Investor Sentiment
- Whether Pelthos can leverage the ROTH Conference to attract new investors and partnerships.
Related topics